Systimmune said the FDA cleared its IND application for SI-B037, a bispecific antibody targeting immunosuppression and other synergistic mechanisms. The company characterized SI-B037 as designed to engage complementary pathways that may enhance antitumor immune activity. The IND clearance moves the program closer to early clinical evaluation in advanced malignancies, with the regulatory milestone supporting the next step toward first-in-human dosing. Details on study design were not provided in the release. The action adds another asset to the bispecific pipeline category as sponsors continue to compete on immunology-based, mechanism-dense therapies.